A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jennifer L. Crombie(Dana-Farber Cancer Institute), Geoffrey Shouse(City Of Hope National Medical Center), Robert Redd(Harvard University), Oreofe O. Odejide(Dana-Farber Cancer Institute), Margaret A. Shipp(Broad Institute), Alex F. Herrera(City of Hope), Caron A. Jacobson(Dana-Farber Cancer Institute), Erin M. Parry(Broad Institute), Philippe Armand(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Reid W. Merryman(Harvard University), Nancy L. Bartlett(Washington University in St. Louis), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Sobana Balasubramanian(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Celeste Carey(Dana-Farber Cancer Institute), Victoria Patterson(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k